Cisplatin

BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Retrieved on: 
Dienstag, Oktober 17, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, SSE, Congress, Abstract, ORR, Tislelizumab, Cisplatin, OS, PD-L1, XELOX, BGNE, Survival, CEST, ESMO, ITT, Oxaliplatin, Kuwait Cancer Control Center, PFS, European Society for Medical Oncology, European Society of Gynaecological Oncology, FP, Patient, Sun, Pharmaceutical industry, BeiGene

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced results from the final analysis of the Phase 3 RATIONALE 305 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) in the intent-to-treat (ITT) population as a first-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

Key Points: 
  • BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced results from the final analysis of the Phase 3 RATIONALE 305 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) in the intent-to-treat (ITT) population as a first-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
  • Study results will be featured as a late-breaking oral presentation on October 21 at 5:25 p.m. CEST at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract #LBA80).
  • “These data show that tislelizumab plus chemotherapy resulted in significant overall survival improvement compared with chemotherapy alone in the intent-to-treat patient group.
  • Median progression-free survival (PFS) for tislelizumab plus chemotherapy was 6.9 months vs. 6.2 months respectively; (HR: 0.78 [95% CI: 0.67, 0.90]).

EMD Serono to Present Latest Research from Oncology Portfolio at ESMO 2023

Retrieved on: 
Montag, Oktober 16, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Annual general meeting, Cancer, Health care, Food, UC, MCC, Abstract, IAP, NSCLC, Apoptosis, European Society for Medical Oncology, Cisplatin, OS, Ageing, Safety, Lung cancer, US Foods, Angela Merkel, Patient, FDA, ESMO, Chemoradiotherapy, Skin cancer, Phase, Booth, Merck, LA, Neck, Maintenance, Bladder cancer, Merck Group, Lung, Head, Merck Serono, Avelumab, Progression-free survival, MET, SCCHN, Pharmaceutical industry, Nightclub

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting, October 20-24, Madrid, Spain.

Key Points: 
  • EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting, October 20-24, Madrid, Spain.
  • Additional presentations and activities at ESMO highlight the company’s efforts to improve the lives of people with cancer.
  • New analyses and real-world evidence to be presented at ESMO reinforce the role of the JAVELIN Bladder regimen in this setting.
  • In September 2023, the accelerated approval in the US was converted into full approval for use of BAVENCIO for the treatment of metastatic MCC.

Merck to Present Latest Research from Oncology Portfolio at ESMO 2023

Retrieved on: 
Montag, Oktober 16, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Annual general meeting, Cancer, Cetuximab, UC, Food, MCC, Biomarker, Abstract, IAP, NSCLC, Apoptosis, European Society for Medical Oncology, Cisplatin, OS, Ageing, Safety, Lung cancer, US Foods, Angela Merkel, Patient, FDA, ESMO, Chemoradiotherapy, Skin cancer, Phase, Booth, LA, Neck, Maintenance, Bladder cancer, Lung, Head, Avelumab, Progression-free survival, MET, SCCHN, Pharmaceutical industry, Nightclub, Merck

Merck, a leading science and technology company, today announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting, October 20-24, Madrid, Spain.

Key Points: 
  • Merck, a leading science and technology company, today announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting, October 20-24, Madrid, Spain.
  • Presentations at the meeting encompass new analyses for the standard-of-care medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab).
  • Additional presentations and activities at ESMO highlight the company’s efforts to improve the lives of people with cancer.
  • New analyses and real-world evidence to be presented at ESMO reinforce the role of the JAVELIN Bladder regimen in this setting.

U.S. Cancer Centers Continue to See Chemotherapy Shortages, According to Update from NCCN

Retrieved on: 
Donnerstag, Oktober 5, 2023
United, Hydrocortisone, White, National Comprehensive Cancer Network, Advocacy, Medicaid, U.S. federal government response to the COVID-19 pandemic, MD, Cisplatin, Federation, National Cancer Institute, Cancer, Medicare, Database, Carboplatin, Methotrexate, MSW, Attention, Patient, White House, NCCN, Nursing, Dietary supplement, Policy

PLYMOUTH MEETING, Pa., Oct. 5, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a non-profit alliance of leading cancer centers across the United States—has released a follow-up survey on the ongoing chemotherapy shortages: 72% of the centers surveyed continue to experience a shortage of carboplatin and 59% are still seeing a shortage of cisplatin. Overall, 86% of centers surveyed reported experiencing a shortage of at least one type of anti-cancer drug.

Key Points: 
  • Overall, 86% of centers surveyed reported experiencing a shortage of at least one type of anti-cancer drug.
  • 86% of centers surveyed reported experiencing a shortage of at least one type of anti-cancer drug.
  • The NCCN Best Practices Committee originally shared survey results in June 2023 , which found that 93% of cancer centers surveyed at that time were experiencing a shortage of carboplatin and 70% lacked a steady supply of cisplatin.
  • Both surveys focused on two platinum-based generic chemotherapy medications that are recommended for treating hundreds of different cancer scenarios according to the NCCN Drugs & Biologics Compendium ( NCCN Compendium ®).

Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Month

Retrieved on: 
Mittwoch, Oktober 4, 2023
Therapy, ASTRO, RECIST, Cancer, Progression-free survival, Head, NANO, Cisplatin, Radiation therapy, Neck, Sepsis, CRR, Death, Radiation, MD, Patient, Lymph, Comorbidity, HNSCC, Webcast, Observation, Nanobiotix, IMRT, Ageing, Neoplasm, MOS, Principal, RT, NBTXR3, Society, ACCI, ORR, Safety, Pharmaceutical industry, Euronext

During the call, Laurent Levy, chief executive officer, will review the Study 102 final data before taking questions from participants.

Key Points: 
  • During the call, Laurent Levy, chief executive officer, will review the Study 102 final data before taking questions from participants.
  • Surgery or definitive cisplatin-based chemotherapy are the current standard of care for patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC; head and neck cancer).
  • One third of these patients, however, cannot tolerate cisplatin due to complications such as age-related frailty or other medical conditions (comorbidities).
  • At the final readout, an independent review committee determined a median Progression-Free Survival (mPFS) of 16.9 months in evaluable patients.

Pacylex Pharmaceuticals's Zelenirstat Shows Potent in vitro Radiosensitization in Human Glioblastoma Models

Retrieved on: 
Dienstag, Oktober 3, 2023
NIH, Radiation, Cisplatin, Temozolomide, Radiation therapy, Telescopic sight, Medical imaging

To view the full announcement, including downloadable images, bios, and more, click here .

Key Points: 
  • To view the full announcement, including downloadable images, bios, and more, click here .
  • Zelenirstat, a myristoylation inhibitor in clinical development, markedly improved the ability of radiation to kill cultured human brain cancer cells.
  • Zelenirstat was more effective than clinically used radiosensitizers, including temozolomide, cisplatin, and 5-fluorouracil.
  • Orally administered zelenirstat is predicted to cross the blood brain barrier more efficiently than temozolomide, the current standard of care radiosensitizer for aggressive brain cancers.

Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Retrieved on: 
Freitag, September 22, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Carcinoma, Progression-free survival, Survival, MRK, Head, Cisplatin, Cohort study, Carboplatin, PFS, Merck & Co., Phase 3, HIV disease progression rates, Patient, Brentuximab vedotin, NYSE, ORR, Pharmaceutical industry, Seagen, Merck

The trial enrolled patients who may or may not be eligible for treatment with cisplatin-based chemotherapy, regardless of PD-L1 status.

Key Points: 
  • The trial enrolled patients who may or may not be eligible for treatment with cisplatin-based chemotherapy, regardless of PD-L1 status.
  • In the trial, KEYTRUDA in combination with enfortumab vedotin met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), demonstrating a statistically significant and clinically meaningful improvement versus chemotherapy in patients with previously untreated la/mUC.
  • The combination also showed a statistically significant improvement in overall response rate (ORR), a key secondary endpoint, versus chemotherapy.
  • “This is an important milestone, as many patients with advanced urothelial carcinoma still experience disease progression following chemotherapy.

Sensorion Reports 2023 First Half Results

Retrieved on: 
Mittwoch, September 20, 2023
Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Genetics, Clinical Trials, Other Health, GMP, US Foods, Ear, PTA, European Medicines Agency, Huber loss, G&A, Malignancy, Patient, Institut Pasteur Korea, R, Cisplatin, POC, Pasteur Institute, Good manufacturing practice, Hearing loss, Congenital hearing loss, Cochlear Limited, IHC, Bioreactor, Perilymph, EMA, Platinum, Ototoxicity, HIV disease progression rates, Hearing, CIO, FDA, IND, Health care, Cochlea, Cell, AAV, GJB2, Presbycusis, Audiogram, Hertz, ANSM, KOL, Partnership, Neoplasm, Concept, Clinical trial, Quality of life, CTA, Medication, CDMO, Orphan, Pharmaceutical industry, Dentistry, Vaccine, Medical device, Cryptocurrency, Rare-earth element

In the first half of 2023, Sensorion achieved a major development milestone by completing the preclinical package, and successfully producing the GMP dual AAV OTOF-GT batches at 200L clinical scale.

Key Points: 
  • In the first half of 2023, Sensorion achieved a major development milestone by completing the preclinical package, and successfully producing the GMP dual AAV OTOF-GT batches at 200L clinical scale.
  • In April 2023, Sensorion announced the candidate selection for GJB2-GT during its R&D Day focusing on gene therapy.
  • The first patient was enrolled in December 2022 and Sensorion anticipates the publication of the preliminary results in H2 2023.
  • The annual accounts on June 30, 2023, drawn up according to IFRS standards and approved by the Board of Directors on September 18, 2023.

AUA Releases Amendment to the Diagnosis and Treatment of Early-Stage Testicular Cancer Guideline

Retrieved on: 
Donnerstag, September 14, 2023
Cancer, IIB, Teratoma, Guideline, Retroperitoneal space, AUA, IIA, American Urological Association, Bleomycin, Toxicity, Cisplatin, Literature, SUFU, Testicular cancer, Etoposide, Estate (law), Patient, Surveillance, Diagnosis, Rush University Medical Center, Tumor antigen, ULR, Dentistry, Medical imaging, Medical device

BALTIMORE, Sept. 14, 2023 /PRNewswire/ -- Today the American Urological Association (AUA) released the 2023 clinical practice guideline amendment for the diagnosis and treatment of early-stage testicular cancer.

Key Points: 
  • BALTIMORE, Sept. 14, 2023 /PRNewswire/ -- Today the American Urological Association (AUA) released the 2023 clinical practice guideline amendment for the diagnosis and treatment of early-stage testicular cancer.
  • Testicular cancer is the most common solid malignancy in young males and is relatively rare, with outcomes defined by specific cancer and patient-related factors.
  • "Since the last testicular cancer guideline was released, the model for management has substantially changed, making an amendment like this critical to effectively treat and manage testicular cancer."
  • Diagnosis and treatment of early-stage testicular cancer: AUA Guideline amendment 2023.

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Retrieved on: 
Donnerstag, September 7, 2023
Neuroblastoma, Hearing loss, Survival, Food and Drug Administration, Osteosarcoma, COG, Cisplatin, Medulloblastoma, Literacy, RESEARCH, Germ cell tumor, Incidence, FENC, Ototoxicity, Patient, Risk, Kool-Aid, Hepatoblastoma, PARK, TSX, FDA, Food, Safety, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences.
  • The management team will also host one-on-one investor meetings at the conferences.
  • It is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients.
  • In the U.S. and Europe, it is estimated that, annually, more than 10,000 children may receive platinum-based chemotherapy.